Results for adcetris translation from English to Maltese

what is adcetris?
x’inhu adcetris?

how does adcetris work?
kif jaħdem adcetris?

what is adcetris used for?
għal xiex jintuża adcetris?

how has adcetris been studied?
kif ġie studjat adcetris?

other information about adcetris
informazzjoni oħra dwar adcetris

what is the risk associated with adcetris?
x’inhu r-riskju assoċjat ma’ adcetris?

what information is still awaited for adcetris?
liema informazzjoni għadha mistennija għal adcetris?

adcetris has been given ‘conditional approval’.
adcetris ingħata ‘approvazzjoni b'kundizzjoni’.

what benefit has adcetris shown during the studies?
liema benefiċċju wera adcetris waqt l-istudji mwettqa?

adcetris is a medicine that contains the active substance brentuximab vedotin.
adcetris huwa mediċina li fiha s-sustanza attiva brentuximab vedotin.

what measures are being taken to ensure the safe and effective use of adcetris?
x’miżuri qed jittieħdu biex jiġi żgurat l-użu sigur u effikaċi ta’ adcetris?

for the full list of all side effects and restrictions with adcetris, see the package leaflet.
għal-lista sħiħa tal-effetti sekondarji u r-restrizzjonijiet kollha b’adcetris, ara l-fuljett ta' tagħrif.

the effects of adcetris were first tested in experimental models before being studied in humans.
l-effetti ta’ adcetris ġew l-ewwel analizzati fuq mudelli sperimentali qabel ma ġew studjati fil-bnedmin.

the committee further noted that the overall safety profile of adcetris was acceptable for these patients.
il-kumitat innota wkoll li l-profil ġenerali tas-sigurtà ta’ adcetris kien aċċettabbli għal dawn il-pazjenti.

adcetris should be given under the supervision of a doctor who has experience in the use of cancer treatments.
adcetris jenħtieġ li jingħata taħt is-superviżjoni ta’ tabib li għandu l-esperjenza fl-użu ta’ kura kontra l- kanċer.

in salcl, adcetris has been studied in one main study in 58 salcl patients whose cancer had come back or had not responded to treatment.
fl-salcl, adcetris ġie studjat fi studju ewlieni wieħed fuq 58 pazjent bl-salcl li l-kanċer tagħhom kien reġa' tfaċċa jew li ma kinux irrispondew għall-kura.

adcetris must not be used together with bleomycin (another cancer medicine) as this combination is damaging to the lungs.
adcetris ma għandux jintuża flimkien ma bleomycin (mediċina oħra kontra l-kanċer) peress li din il- kombinazzjoni hija ta' ħsara għall-pulmuni.

recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of adcetris have been included in the summary of product characteristics and the package leaflet.
ir-rakkomandazzjonijiet u l-prekawzjonijiet li għandhom jiġu segwiti mill-professjonisti fil-qasam tal- kura tas-saħħa u mill-pazjenti għall-użu sigur u effettiv ta' adcetris ġew inklużi wkoll fis-sommarju tal- karatteristiċi tal-prodott u fil-fuljett ta' tagħrif.

for more information about treatment with adcetris, read the package leaflet (also part of the epar) or contact your doctor or pharmacist.
għal aktar informazzjoni dwar kura b’adcetris, aqra l-fuljett ta’ tagħrif (parti mill-epar ukoll) jew ikkuntattja lit-tabib jew lill-ispiżjar tiegħek.

the active substance in adcetris, brentuximab vedotin, is made up of a cd30 monoclonal antibody (a type of protein that attaches to cd30).
is-sustanza attiva f'adcetris, il-brentuximab vedotin, hija magħmula minn antikorp monoklonali ta’ cd30 (tip ta’ proteina li teħel ma’ cd30).